About Delix Therapeutics
Delix Therapeutics is a Healthcare company based in Menlo Park (United States) founded in 2019 by Nicholas Haft and David E Olson. Non-hallucinogenic therapeutics for neurological disorders are developed. Delix Therapeutics has raised $170 million across 6 funding rounds from investors including Comerica, HHS and RA Capital. The company has 7 employees. Delix Therapeutics offers products and services including Neuroplastogens. Its focus areas include Life Sciences, Neurology, Drugs and Psychiatric. Its legal entity is Delix Therapeutics, Inc. Its competitors include MindMed, CB Therapeutics and Mindstate; 2 of its 3 listed competitors have raised funding.
Company details
Delix Therapeutics was founded in 2019 and is based in Menlo Park, United States. Small molecule-based, non-hallucinogenic versions of psychedelic compounds are developed by the company to address depression, anxiety, and post-traumatic stress disorders. Operations focus on creating therapeutic solutions within the biotechnology sector for multiple neurological conditions, enabling treatment options for healthcare providers.
- Headquarters Menlo Park, United States
- Employees 7
- Founders Nicholas Haft, David E Olson
- SectorsHealthcare
- Website delixtherapeutics.com
- Social LinkedIn
- Legal Name Delix Therapeutics, Inc
- Total Equity Funding$170M (USD)
in 6 rounds
- Latest Funding Round$100M (USD), Series C
Nov 2026
- InvestorsComerica
& 25 more
- Employee Count7
Products & Services of Delix Therapeutics
Delix Therapeutics offers a comprehensive portfolio of products and services, including Neuroplastogens.
Compounds that induce neuroplasticity to treat brain health conditions.
Funding Insights of Delix Therapeutics
Delix Therapeutics has successfully raised a total of $170M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $100 million completed in November 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $170M
- Total Rounds 6
- Last Round Series C — $100M
- First Round $70M
(Sep 2021)
- Investors Count 26
All 6 funding rounds of Delix Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2026 | $100M | Series C | – | Johnson & Johnson, SV Health Investors | |
| Jun 2024 | $825,000 | Grant | – | – | |
| Sep 2023 | $319,313 | Grant | – | – | |
| Jan 2022 | $30M | Debt – Convertible | – | – | – |
| Jan 2022 | $10M | Debt – Venture | – | – | |
| Sep 2021 | $70M | Series A | – | Artis Ventures, RA Capital Management |
26 investors in total: 26 institutional.
Investors in Delix Therapeutics
Delix Therapeutics has secured backing from 26 investors, including institutional and venture fund investors. Prominent investors backing the company include Comerica, HHS and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage startups are invested in by Artis Ventures. | av.co | San Francisco, United States | ||
Investment in cannabis industry startups is facilitated by Casa Verde. | 2021 | casaverdecapital.com | ||
Venture capital fund focused on early-stage biotech, life sciences, IT, and multiple sectors | dolbyventures.com | San Francisco, United States | ||
Venture capital fund backed by the Christian family office | presight.vc | West Hollywood, United States | ||
Limited information is provided about Palo Santo's activities. | palosanto.vc | |||
Noetic Fund is engaged in global investments in emerging health technologies. | noeticfund.com | Toronto, Canada | ||
Venture capital firm focused on biotechnology and healthcare sectors | saya.bio | |||
Early-stage venture capital investments are made in specific industry verticals. | vvp.vc | Palo Alto, United States | ||
Venture capital fund backed by single family office | r2.ventures | |||
PsyMed Ventures is focused on funding mental health innovations. | 2022 | psymed.ventures |
Investor details for Delix Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Delix Therapeutics
19 people are tracked at Delix Therapeutics (10 in leadership, 9 in board & advisors); the tracked headcount is 7.
| Name | Role | Group |
|---|---|---|
Nicholas Haft | Co-Founder & Chairman | Leadership |
David E Olson | Co-Founder & CSO | Leadership |
Retsina Meyer | Head of Corporate Strategy | Leadership |
David Olson | CIO, Head of SAB, Co-Founder | Leadership |
Mark Rus | CEO | Leadership |
Tricia Mccall | Chief People Officer | Leadership |
Matt Gorman | CFO | Leadership |
Eliseo Salinas | Head of Research & Development | Leadership |
Mike Bower | Associate Director, Computational Chemist | Leadership |
Milan Chytil | Senior Director Of Medicinal Chemistry | Leadership |
Vasudev Bailey | Director | Board & advisors |
Nick Haft | Director | Board & advisors |
John Krystal | Advisor | Board & advisors |
Florence Wagner | Advisor | Board & advisors |
Craig Lindsley | Advisor | Board & advisors |
Conor Liston | Advisor | Board & advisors |
Jacob Hooker | Advisor | Board & advisors |
Stephen Stahl | Advisor | Board & advisors |
Michael Cola | Advisor | Board & advisors |
Complete people profiles for Delix Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Delix Therapeutics
3 dated milestones of Delix Therapeutics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Delix Therapeutics is founded.
- Funding First funding round of $70.0M.
- Funding Latest funding round, Series C, of $100.0M.
Competitors of Delix Therapeutics
Delix Therapeutics has 3 listed competitors in our database, 2 of them funded. They include MindMed, CB Therapeutics and Mindstate.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| mindmed.co | 2019 | New York, United States | 74 | Psychedelic-based therapies for brain health disorders are developed. | ||
| cbthera.com | 2015 | San Diego, United States | $150,000 | 15 | Biosynthetic cannabinoids are produced from sugar using engineered microbes. | |
| mindstate.design | 2021 | Pittsburgh, United States | $24.32M | Psychedelic-based therapeutics for mental health conditions are developed. |
Detailed competitors of Delix Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Delix Therapeutics
The website of Delix Therapeutics (delixtherapeutics.com) receives about 3.2K visits a month.
- Monthly visits3.2K
▼ 23.8% vs previous month
Top companies in Neurology
3 companies that operate in the same segment as Delix Therapeutics (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Delix Therapeutics
Complete news archive for Delix Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Delix Therapeutics
Delix Therapeutics was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Delix Therapeutics is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Delix Therapeutics is a funded company, having raised a total of $170M across 6 funding rounds to date. The company's 1st funding round was a Series A of $70M, raised on Sep 2021.
Delix Therapeutics has 7 employees.
Delix Therapeutics was founded in 2019 and is based in Menlo Park, United States. Small molecule-based, non-hallucinogenic versions of psychedelic compounds are developed by the company to address depression, anxiety, and post-traumatic stress disorders. Operations focus on creating therapeutic solutions within the biotechnology sector for multiple neurological conditions, enabling treatment options for healthcare providers.
Delix Therapeutics's top competitors include MindMed, CB Therapeutics and Mindstate.
Delix Therapeutics offers Neuroplastogens.
Delix Therapeutics has 26 investors. Key investors include Comerica, HHS, RA Capital, Artis Ventures, and Casa Verde.
Delix Therapeutics operates through Delix Therapeutics, Inc.